NasdaqGS - Nasdaq Real Time Price USD
Incyte Corporation (INCY)
108.46 +4.06 (+3.89%)
At close: 4:00:01 PM EDT
108.85 +0.39 (+0.36%)
After hours: 7:03:26 PM EDT
Trade Incyte on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for INCY
- Previous Close
104.40 - Open
105.53 - Bid 99.52 x 200
- Ask 115.56 x 200
- Day's Range
104.49 - 109.10 - 52 Week Range
66.83 - 112.29 - Volume
1,931,939 - Avg. Volume
1,597,233 - Market Cap (intraday)
21.668B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
15.32 - EPS (TTM)
7.08 - Earnings Date (est.) Jul 28, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
110.26
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
INCY
9.81%
S&P 500 (^GSPC)
7.49%
1-Year Return
INCY
57.17%
S&P 500 (^GSPC)
20.78%
3-Year Return
INCY
73.67%
S&P 500 (^GSPC)
69.22%
5-Year Return
INCY
25.93%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
20.86B
Enterprise Value
16.88B
Trailing P/E
14.75
Forward P/E
13.55
PEG Ratio (5yr expected)
0.36
Price/Sales (ttm)
3.95
Price/Book (mrq)
3.71
Enterprise Value/Revenue
3.15
Enterprise Value/EBITDA
9.02
Financial Highlights
Profitability and Income Statement
Profit Margin
26.71%
Return on Assets (ttm)
13.89%
Return on Equity (ttm)
30.82%
Revenue (ttm)
5.36B
Net Income Avi to Common (ttm)
1.43B
Diluted EPS (ttm)
7.08
Balance Sheet and Cash Flow
Total Cash (mrq)
4.02B
Total Debt/Equity (mrq)
0.70%
Levered Free Cash Flow (ttm)
558.87M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreIncyte Earnings: Strong Opzelura Sales, Positive Povorcitinib Data as Jakafi Patent Loss Approaches
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
RatingPrice TargetIncyte Earnings: Strong Opzelura Sales, Positive Povorcitinib Data as Jakafi Patent Loss Approaches
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
RatingPrice TargetRaising earnings estimates
Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Opzelura, Iclusig, Pemazyre, Niktimvo, and Olumiant. Jakafi treats polycythemia vera, a type of blood cancer; myelofibrosis, a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease. Opzelura treats eczema and vitiligo, Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats alopecia areata and rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer; Zynyz, an anticancer medication; and Niktimvo, for chronic graft-versus-host disease. There are also several active Phase 2 and 3 programs in oncology. The shares are a component of the S&P 500 Index.
RatingPrice TargetThe major stock indices are broadly higher at midday on Thursday. The newsflow
The major stock indices are broadly higher at midday on Thursday. The newsflow is heavily focused on earnings, but new data on GDP and a slight pullback in the price of oil are also factors. Crude oil is at $104 per barrel. The yield on the 10-year note is at 4.39%. The volatility index, the VIX, is at 18.